Drug Information

Drug General Information
Drug ID
D0I6RI
Former ID
DNCL002543
Drug Name
GRNVAC1
Drug Type
Vaccine
Indication Acute myeloid leukemia [ICD9: 205; ICD10:C92.0] Phase 2 [522080]
Company
Argos Therapeutics
Target and Pathway
Target(s) Telomerase reverse transcriptase Target Info [531368]
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Validated targets of C-MYC transcriptional activation
Regulation of Telomerase
IL2 signaling events mediated by PI3K
Regulation of nuclear beta catenin signaling and target gene transcription
HIF-1-alpha transcription factor network
Reactome Formation of the beta-catenin:TCF transactivating complex
References
Ref 522080ClinicalTrials.gov (NCT00510133) A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML). U.S. National Institutes of Health.
Ref 531368Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.